These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 38536937

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
    Berhanu A, Wilson RL, Kirkwood-Watts DL, King DS, Warren TK, Lund SA, Brown LL, Krupkin AK, Vandermay E, Weimers W, Honeychurch KM, Grosenbach DW, Jones KF, Hruby DE.
    J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of the modified vaccinia Ankara virus vaccine and the replication-competent vaccine ACAM2000 in monkeypox prevention.
    Kandeel M, Morsy MA, Abd El-Lateef HM, Marzok M, El-Beltagi HS, Al Khodair KM, Albokhadaim I, Venugopala KN.
    Int Immunopharmacol; 2023 Jun; 119():110206. PubMed ID: 37087871
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.
    Kaufman DR, Goudsmit J, Holterman L, Ewald BA, Denholtz M, Devoy C, Giri A, Grandpre LE, Heraud JM, Franchini G, Seaman MS, Havenga MJ, Barouch DH.
    J Virol; 2008 Jul; 82(14):6829-37. PubMed ID: 18448519
    [Abstract] [Full Text] [Related]

  • 7. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
    Pittman PR, Hahn M, Lee HS, Koca C, Samy N, Schmidt D, Hornung J, Weidenthaler H, Heery CR, Meyer TPH, Silbernagl G, Maclennan J, Chaplin P.
    N Engl J Med; 2019 Nov 14; 381(20):1897-1908. PubMed ID: 31722150
    [Abstract] [Full Text] [Related]

  • 8. Mpox global health emergency: Insights into the virus, immune responses, and advancements in vaccines PART II: Insights into the advancements in vaccines.
    Prompetchara E, Ketloy C, Khawsang C, Palaga T, Ruxrungtham K.
    Asian Pac J Allergy Immunol; 2024 Sep 14; 42(3):191-206. PubMed ID: 39417768
    [Abstract] [Full Text] [Related]

  • 9. Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines.
    Meseda CA, Atukorale V, Kuhn J, Schmeisser F, Weir JP.
    PLoS One; 2016 Sep 14; 11(2):e0149364. PubMed ID: 26895072
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Protection of mice against the highly pathogenic VVIHD-J by DNA and fowlpox recombinant vaccines, administered by electroporation and intranasal routes, correlates with serum neutralizing activity.
    Bissa M, Quaglino E, Zanotto C, Illiano E, Rolih V, Pacchioni S, Cavallo F, De Giuli Morghen C, Radaelli A.
    Antiviral Res; 2016 Oct 14; 134():182-191. PubMed ID: 27637905
    [Abstract] [Full Text] [Related]

  • 14. An overview on mRNA-based vaccines to prevent monkeypox infection.
    Natami M, Gorgzadeh A, Gholipour A, Fatemi SN, Firouzeh N, Zokaei M, Mohammed Ali SH, Kheradjoo H, Sedighi S, Gholizadeh O, Kalavi S.
    J Nanobiotechnology; 2024 Mar 01; 22(1):86. PubMed ID: 38429829
    [Abstract] [Full Text] [Related]

  • 15. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.
    Golden JW, Josleyn MD, Hooper JW.
    Vaccine; 2008 Jun 25; 26(27-28):3507-15. PubMed ID: 18485547
    [Abstract] [Full Text] [Related]

  • 16. Systemically administered DNA and fowlpox recombinants expressing four vaccinia virus genes although immunogenic do not protect mice against the highly pathogenic IHD-J vaccinia strain.
    Bissa M, Pacchioni SM, Zanotto C, De Giuli Morghen C, Illiano E, Granucci F, Zanoni I, Broggi A, Radaelli A.
    Virus Res; 2013 Dec 26; 178(2):374-82. PubMed ID: 24050999
    [Abstract] [Full Text] [Related]

  • 17. Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates.
    Mucker EM, Freyn AW, Bixler SL, Cizmeci D, Atyeo C, Earl PL, Natarajan H, Santos G, Frey TR, Levin RH, Meni A, Arunkumar GA, Stadlbauer D, Jorquera PA, Bennett H, Johnson JC, Hardcastle K, Americo JL, Cotter CA, Koehler JW, Davis CI, Shamblin JD, Ostrowski K, Raymond JL, Ricks KM, Carfi A, Yu WH, Sullivan NJ, Moss B, Alter G, Hooper JW.
    Cell; 2024 Oct 03; 187(20):5540-5553.e10. PubMed ID: 39236707
    [Abstract] [Full Text] [Related]

  • 18. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates.
    Hooper JW, Custer DM, Thompson E.
    Virology; 2003 Feb 01; 306(1):181-95. PubMed ID: 12620810
    [Abstract] [Full Text] [Related]

  • 19. Progress and prospects on vaccine development against monkeypox infection.
    Saadh MJ, Ghadimkhani T, Soltani N, Abbassioun A, Daniel Cosme Pecho R, Taha A, Jwad Kazem T, Yasamineh S, Gholizadeh O.
    Microb Pathog; 2023 Jul 01; 180():106156. PubMed ID: 37201635
    [Abstract] [Full Text] [Related]

  • 20. Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus.
    Chiuppesi F, Zaia JA, Gutierrez-Franco MA, Ortega-Francisco S, Ly M, Kha M, Kim T, Dempsey S, Kar S, Grifoni A, Sette A, Wussow F, Diamond DJ.
    Commun Med (Lond); 2024 Feb 16; 4(1):19. PubMed ID: 38366141
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.